Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Analysts are encouraged by Syfovre's resilience as an eye treatment despite competition from ... another rare kidney damage disease, paroxysmal nocturnal hemoglobinuria. There's less opportunity ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Regulatory risks and competition exist ... and Cemdisiran Paroxysmal Nocturnal Hemoglobinuria. The company also has vutrisiran in Phase 3 trials for ATTR amyloidosis with cardiomyopathy.

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH ... There's other competition looming in PNH however, as Apellis Pharmaceuticals won FDA approval ...

Based on these analyses, Rallybio believes that there is an opportunity to pursue indications beyond generalized myasthenia gravis, including paroxysmal nocturnal hemoglobinuria ... or other ...

We expect to present updated results for one potential indication Paroxysmal Nocturnal Hemoglobinuria ... millions and millions of injections our competition may have brought something forth ...

The threat of biosimilar competition to its cash cow has ... become available for each of its approved indications: paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...